[Abstract] Aspergillus fumigatus is a ubiquitous fungal pathogen that forms airborne conidia. The process of restricting conidial germination into hyphae by lung leukocytes is critical in determining infectious outcomes. Tracking the outcome of conidia-host cell encounters in vivo is technically challenging and an obstacle to understanding the molecular and cellular basis of antifungal immunity in the lung. Here, we describe a method that utilizes a genetically engineered Aspergillus strain [called FLARE (Jhingran et al., 2012; Espinosa et al., 2014; Heung et al., 2015) ] to monitor conidial phagocytosis and killing by leukocytes within the lung environment at single encounter resolution.
Materials and Reagents
2. Filter the conidial suspension sequentially through a 100 μm and a 40 μm cell strainer to eliminate hyphal fragments. Centrifuge the filtered suspension at 400 x g for 5 min. Discard the supernatant and resuspend the conidial pellet in 10 ml PBST.
3. Count the conidia using a hemocytometer and adjust the final concentration to 5-6 x 10 8 conidia per ml.
4. Centrifuge desired amount of conidial suspension at 400 x g for 5 min, discard supernatant and resuspend the pellet in 50 mM NaHCO3 (pH 9.5) maintaining the final concentration as 5 x 10 8 conidia per ml.
5. Add 0.5 mg/ml Biotin-XX, SSE (6-((6-((biotinoyl)amino)hexanoyl)-amino) hexanoic acid), sulfosuccinimidyl ester, sodium salt (stock 50 mg/ml in DMSO) to the conidial suspension and incubate with rotation in the dark.
Note: A minimum of 2 h incubation is recommended for efficient biotinylation. This step can be extended for up to 12 h (O/N incubation). The tubes containing biotinylated conidia should be covered with aluminum foil at all times.
6. Centrifuge and decant the supernatant. Neutralize unbound biotin by resuspending the pellets and incubating conidia in 0.1 M Tris-HCl (pH 8.0) for 30 min with constant rotation.
7. Repeat step A6 and resuspend the biotinylated conidia in (indicate volume) PBS containing 0.02 mg/ml AF633-streptavidin (stock 2 mg/ml in PBS). Incubate for 30 min at RT with constant rotation.
8. Wash once with PBST and adjust the concentration to 6 x 10 7 per ml for intratracheal challenge. 2. Anaesthetize mice using an isoflurane unit that pumps a mixture of isoflurane (3.5%, vol/vol) and oxygen in an anesthesia chamber. 3. Insert a BALF catheter into the mouse trachea and repeatedly inject 0.5 ml of ice cold PBS/5% FBS (from the "input" syringe filled with 3 ml of PBS/5% FBS) and then aspirate BALF from 7 www.bio-protocol.org/e1927 Vol 6, Iss 18, Sep 20, 2016 the inflated lungs into the initially unfilled "output" syringe via a 3-way stop cock. Typically, we inject a total of 3 ml and recover 2.5 ml of BALF in the output syringe. The 3-way stopcock is adjusted after each injection and aspiration step to ensure that BALF is captured in the output syringe.
4. Transfer BALF into empty tubes and store on ice.
5. Collect lungs in tubes containing 2 ml ice cold PBS and store on ice. 4. Briefly spin tubes (300 x g for 1 min) to bring cells at the bottom and using a pipette, transfer the contents into fresh 15 ml tubes.
Note: All subsequent steps are to be performed at 4 °C unless otherwise mentioned.
5. Centrifuge the tubes at 300 x g for 5 min, discard supernatant and lyse RBCs by resuspending pellet in 1 ml of 1x RBC lysis buffer for 5 min at RT.
6. Following RBC lysis, add 9 ml of ice cold 5% FBS/PBS to each tube and pass the entire 10 ml lung suspension through a 100 μm cell strainer into fresh 15 ml tubes.
7. Centrifuge tubes, discard supernatant and resuspend cells in 2 ml ice cold 5% FBS/PBS. 
